해외뉴스
(해외) 합성생물학 뉴스
해외뉴스
총 게시물 510건
| 420 | 기술 |
New approach for efficient engineering of cell and gene therapies
A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods. The approach could also power the development of advanced cell therapies for cancers and other diseases, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania. In the study, which appeared this week in Nature Biotechnology, researchers found that protein fragments used by some viruses to help them get into cells could also be used to get CRISPR-Cas gene editing molecules into cells and their DNA-containing nuclei with extraordinarily high efficiency and low cellular toxicity.
|
| 419 | 기술 |
Synthetic Morphology Lets Scientists Create New Life-Forms
In the collection of the Peabody Museum at Harvard University reside the mummified remains of a very peculiar creature. It has the shrunken head, torso and arms of a monkey, but from the waist down, it is a fish. This bizarre hybrid was bought by Moses Kimball, founder of the Boston Museum, from the family of a sea captain. Kimball leased it in 1842 to the impresario P. T. Barnum for his popular American Museum in New York City. Barnum claimed it was a mermaid found in Fiji.
|
| 418 | 산업 |
Solvay teams with Ginkgo Bioworks to expand US footprint
In Massachusetts, Solvay announced a strategic collaboration with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity. Through this multi-year strategic collaboration agreement, Solvay will join forces with Ginkgo to unlock the power of synthetic biology as an enabler of more sustainable chemicals and materials, contributing to the transition towards more environmentally-friendly solutions. This alliance will start by focusing on new sustainable biopolymers, specialties which could tangibly impact a breadth of markets, from home and personal care to agriculture and food.
|
| 417 | 정책 |
GAO Warns of Synthetic Biotechnology Being Used as Weapons
A new report from the U.S. Government Accountability Office (GAO) published on April 17, warns about the potential of synthetic biology technology that can be used to create bioweapons in the future. The report warns outlines how this new technology will become a new industry that could be exploited by foreign adversaries and those looking to cause harm in America. “Synthetic biology could pose a significant threat to national security if it were used for nefarious purposes, such as developing new biological or chemical weapons,” said the agency.
|
| 416 | 정책 |
Meet 10 Amazing Women Telling The Stories Of Synthetic Biology
Synthetic Biology is a relatively new field, and like all new fields, its goals and methods can be easily misinterpreted or misrepresented. For a technology that is threatening to disrupt almost every area of our lives, public perception is key, and it is essential to communicate the full spectrum of capabilities of synthetic biology – both its potential to make good in the world and the immense power and responsibility that come with it.
|
| 415 | 기술 |
Science & Tech Spotlight: Synthetic Biology
Synthetic biology can change the genetic material in viruses, bacteria, yeasts, plants, or animals to give them useful new characteristics. For example, integrating spider DNA makes a silkworm produce super strong, ultra-lightweight silk. The technology could help address challenges in areas such as medicine, agriculture, manufacturing, and the environment. This Science & Tech Spotlight describes some of the benefits of synthetic biology and the challenges ahead. For example, while it could be used to engineer living cells that treat disease from within the body, it could also be used to make bioweapons.
|
| 414 | 정책 |
How much does a biotech pay? Community-generated data tool gives a peak at industry's salaries
When setting up a brand-new biotech, founders have a host of roles to fill and salaries to set. To attract the best talent, compensation has to be just right. A new community-generated data resource from Pillar VC, the Founder-led Biotech Summit and compensation analysis firm Pave seeks to take the guesswork out of the process by summarizing salary ranges from 90 companies. The analysis shows, without surprise, that the C-suite has the highest paid employees in biotech. But breaking that down, chief medical officers, not the CEOs, are bringing home the biggest pay checks. The median salary for a CMO role is $450,000, with a range starting at $225,000 to as high as $459,000. This compares to the median for a CEO, which is $195,000, with a range from $145,000 to $350,000.
|
| 413 | 정책 |
Introduction to Synthetic Biology: An Overview of the Technology
Synthetic biology is an emerging field of science that combines biology, engineering and computer science to create novel biological systems. It has the potential to revolutionize many aspects of life, from medical treatments to agricultural production. In essence, synthetic biology involves taking existing biological systems and re-engineering them to better understand how they work, as well as creating entirely new systems from scratch. Synthetic biology can be used to advance scientific research in a variety of ways. For example, it can be used to develop new treatments, such as gene therapies, for diseases that were previously difficult to treat. It can also be used to engineer more efficient crops that are better able to withstand climate change and are more productive in their native environment. Synthetic biology can even be used to create new organisms, such as bacteria, that can be used for a variety of purposes, such as cleaning up oil spills or producing biofuels.
|
| 412 | 기술 |
The nonlinearity of regulation in biological networks
The extent to which the components of a biological system are (non)linearly regulated determines how amenable they are to therapy and control. To better understand this property termed “regulatory nonlinearity”, we analyzed a suite of 137 published Boolean network models, containing a variety of complex nonlinear regulatory interactions, using a probabilistic generalization of Boolean logic that George Boole himself had proposed. Leveraging the continuous-nature of this formulation, we used Taylor decomposition to approximate the models with various levels of regulatory nonlinearity. A comparison of the resulting series of approximations of the biological models with appropriate random ensembles revealed that biological regulation tends to be less nonlinear than expected, meaning that higher-order interactions among the regulatory inputs tend to be less pronounced. A further categorical analysis of the biological models revealed that the regulatory nonlinearity of cancer and disease networks could not only be sometimes higher than expected but also be relatively more variable. We show that this variation is caused by differences in the apportioning of information among the various orders of regulatory nonlinearity. Our results suggest that there may have been a weak but discernible selection pressure for biological systems to evolve linear regulation on average, but for certain systems such as cancer, on the other hand, to simultaneously evolve more nonlinear rules.
|
| 411 | 기술 |
Developing New Sustainable Biopolymers with Solvay
Today, we are pleased to announce our new strategic collaboration with Solvay, a science company whose technologies bring benefits to many aspects of daily life. Through this multi-year collaboration, we’ll show Solvay how the power of synthetic biology can enable their development of more sustainable chemicals and materials, and contribute to the transition towards environmentally-friendly solutions. This development process will first focus on new sustainable biopolymers, which could tangibly impact a breadth of markets, from home and personal care to agriculture and food. As part of this partnership, Solvay will also acquire a Ginkgo (formerly Zymergen) laboratory in Cambridge, Massachusetts. This acquisition will expand Solvay’s research and innovation (R&I) footprint in the US, provide Solvay access to new talents, and establish a sustainable growth base in synthetic biology in one the most important biotech hubs in the world, accelerating the company’s biotech development plan. With this strategic collaboration and expansion, Solvay will be able to integrate deep competencies in bioinformatics, data science, strain engineering, biocatalysis and fermentation processes. Taking advantage of its location in a biotech talent pool and proximity to facilities and customers in the US, Solvay intends to turn this lab into a cornerstone of its growth strategy in renewable materials and biotechnology.
|